- Patients
- Clinical Research
- Clinical trials
- Ascent 03
2022-07-18T00:00:00.000+10:00
Ongoing
Ascent 03
Ascent 03
Breast cancer
A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumours do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumours do express PD-L1 (Ascent 03 GS-US-592-6238)
A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumours do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumours do express PD-L1 (Ascent 03 GS-US-592-6238)
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Breast cancer
Study Phase
III
Trial Identifiers
Registration number: NCT05382299
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)